Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of oral migalastat (AT1001) in Fabry disease
2007-001838-13Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- May 2007
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Primary endpoint: Treatment-emergent marked laboratory abnormalities. Started May 2007; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2007-001838-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001838-13.